S&P 500
(1.02%) 5 099.96 points
Dow Jones
(0.40%) 38 240 points
Nasdaq
(2.03%) 15 928 points
Oil
(0.11%) $83.66
Gas
(-3.32%) $1.920
Gold
(0.30%) $2 349.60
Silver
(-0.43%) $27.52
Platinum
(0.42%) $924.40
USD/EUR
(0.32%) $0.935
USD/NOK
(0.67%) $11.02
USD/GBP
(0.13%) $0.800
USD/RUB
(-0.07%) $92.11

Обновления в реальном времени для Amgen Inc [AMGN]

Биржа: NASDAQ Сектор: Healthcare Промышленность: Drug Manufacturers—General
Upcoming Earnings Alert

5 days till quarter result
(amc 2024-05-02)

Expected move: +/- 2.37%

BUY
51.02%
return -0.44%
SELL
36.00%
return 7.27%
Последнее обновление26 апр. 2024 @ 23:00

0.22% $ 269.98

Купить 1624 min ago

@ $270.69

Выпущен: 26 апр. 2024 @ 22:51


Доходность: -0.26%


Предыдущий сигнал: апр. 26 - 20:55


Предыдущий сигнал: Продать


Доходность: -0.03 %

Live Chart Being Loaded With Signals

Commentary (26 апр. 2024 @ 23:00):
Profile picture for Amgen Inc

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas...

Stats
Объем за сегодня 2.44M
Средний объем 2.95M
Рыночная капитализация 144.69B
EPS $0 ( 2024-04-25 )
Дата следующего отчета о доходах ( $3.76 ) 2024-05-02
Last Dividend $2.25 ( 2024-02-15 )
Next Dividend $0 ( N/A )
P/E 21.60
ATR14 $5.96 (2.21%)
Insider Trading
Date Person Action Amount type
2024-03-18 Santos Esteban Sell 6 137 Common Stock
2024-03-18 Reese David M Sell 6 202 Common Stock
2024-03-18 Miller Derek Sell 475 Common Stock
2024-03-18 Khosla Rachna Sell 438 Common Stock
2024-03-18 Grygiel Nancy A. Sell 703 Common Stock
INSIDER POWER
58.84
Last 97 transactions
Buy: 472 102 | Sell: 97 922

Объем Корреляция

Длинно: -0.56 (weak negative)
Кратко: -0.27 (neutral)
Signal:(30) Neutral

Amgen Inc Корреляция

10 Самые положительные корреляции
SMIT0.929
CNCE0.926
PLIN0.925
CTIC0.921
RETA0.921
LAWS0.921
PIII0.917
IMTX0.914
OP0.913
OBT0.912
10 Самые отрицательные корреляции
RGLD-0.945
GRFS-0.941
IMVT-0.939
WB-0.936
HCM-0.934
HERA-0.934
SOCL-0.933
HOFT-0.933
IPKW-0.93
HERAU-0.929

Вы знали?

Корреляция - это статистический показатель, описывающий связь между двумя переменными. Он изменяется от -1 до 1, где -1 указывает на идеальную отрицательную корреляцию (при увеличении одной переменной другая уменьшается), 1 указывает на идеальную положительную корреляцию (при увеличении одной переменной другая увеличивается), а 0 указывает на отсутствие корреляции (между переменными нет связи).

Корреляцию можно использовать для анализа связи между любыми двумя переменными, не только акциями. Она широко используется в таких областях, как финансы, экономика, психология и т. д.

Amgen Inc Корреляция - Валюта/Сырье

The country flag -0.20
( neutral )
The country flag -0.20
( neutral )
The country flag 0.00
( neutral )
The country flag -0.16
( neutral )
The country flag 0.01
( neutral )
The country flag -0.11
( neutral )

Amgen Inc Финансовые показатели

Annual 2023
Выручка: $28.19B
Валовая прибыль: $19.74B (70.02 %)
EPS: $12.56
FY 2023
Выручка: $28.19B
Валовая прибыль: $19.74B (70.02 %)
EPS: $12.56
FY 2022
Выручка: $26.32B
Валовая прибыль: $19.92B (75.66 %)
EPS: $12.18
FY 2021
Выручка: $25.98B
Валовая прибыль: $19.53B (75.16 %)
EPS: $10.06

Financial Reports:

No articles found.

Amgen Inc Dividends

(Q3/22) (Q4/22) (Q1/23) (Q2/23) (Q3/23) (Q4/23) (Q1/24) (Q2/24) (Q3/24) (Q4/24)
$1.940
(N/A)
$1.940
(N/A)
$2.13
(N/A)
$2.13
(N/A)
$2.13
(N/A)
$2.13
(N/A)
$2.25
(N/A)
$0
(N/A)
$0
(N/A)
$0
(N/A)

Amgen Inc Dividend Information - Dividend King

Dividend Sustainability Score: 10.00 - good (100.00%) | Divividend Growth Potential Score: 6.55 - Stable (31.06%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information
First Dividend $0.280 2011-08-16
Last Dividend $2.25 2024-02-15
Next Dividend $0 N/A
Payout Date 2024-03-07
Next Payout Date N/A
# dividends 51 --
Total Paid Out $61.13 --
Avg. Dividend % Per Year 2.40% --
Score 5.46 --
Div. Sustainability Score 10.00
Div.Growth Potential Score 6.55
Div. Directional Score 8.29 --
Next Divdend (Est)
(2024-07-01)
$2.30 Estimate 61.99 %
Dividend Stability
0.99 Excellent
Dividend Score
5.46
Pay Frequency
Quarterly
Yearly Payout
Year Amount Yield
2011 $0.560 1.01%
2012 $1.440 2.25%
2013 $1.880 2.11%
2014 $2.44 2.11%
2015 $3.16 1.98%
2016 $4.00 2.53%
2017 $4.60 3.05%
2018 $5.28 2.98%
2019 $5.80 3.02%
2020 $6.40 2.67%
2021 $7.04 3.11%
2022 $7.76 3.42%
2023 $8.52 3.26%
2024 $2.25 0.76%

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.

Top 10 dividend Companies for NASDAQ

Symbol Title Last dividend Frequency Years Dividend Yearly Dividend Score
OXLC Dividend Royal 2023-12-14 Monthly 14 10.00% 8.50
OXSQ Dividend Diamond 2023-12-14 Monthly 21 9.10% 8.50
PSEC Dividend Royal 2023-12-26 Monthly 21 7.04% 8.50
SLVO Dividend Royal 2023-11-20 Monthly 12 10.77% 8.50
QYLD Dividend Royal 2023-11-20 Monthly 11 7.50% 8.50
GAIN Dividend Royal 2023-12-04 Monthly 20 8.19% 8.50
GLDI Dividend Royal 2023-11-20 Monthly 12 7.15% 8.50
HRZN Dividend King 2023-12-18 Monthly 15 6.60% 8.45
USOI Dividend Royal 2023-11-20 Monthly 8 16.70% 8.28
PFLT Dividend King 2023-11-15 Monthly 14 6.50% 8.27

Dividend Sustainability Score (DSS)

RatioActual ValueWeightNormalized ValueScoreRange
netProfitMarginTTM0.2381.5005.237.85[0 - 0.5]
returnOnAssetsTTM0.06911.2007.709.23[0 - 0.3]
returnOnEquityTTM1.0331.50010.0010.00[0.1 - 1]
payoutRatioTTM0.678-1.0003.22-3.22[0 - 1]
currentRatioTTM1.6490.8006.755.40[1 - 3]
quickRatioTTM1.6220.8005.174.13[0.8 - 2.5]
cashRatioTTM0.5951.5007.8110.00[0.2 - 2]
debtRatioTTM0.665-1.50010.00-10.00[0 - 0.6]
interestCoverageTTM3.151.0009.949.94[3 - 30]
operatingCashFlowPerShareTTM15.832.004.729.44[0 - 30]
freeCashFlowPerShareTTM13.762.003.126.24[0 - 20]
debtEquityRatioTTM10.37-1.50010.00-10.00[0 - 2.5]
grossProfitMarginTTM0.7001.0001.6631.663[0.2 - 0.8]
operatingProfitMarginTTM0.3211.0005.575.57[0.1 - 0.6]
cashFlowToDebtRatioTTM0.1311.000-0.383-0.383[0.2 - 2]
assetTurnoverTTM0.2900.800-1.399-1.119[0.5 - 2]
Total Score10.02

Dividend Growth Score (DGS)

RatioActual ValueWeightNormalized ValueScoreRange
peRatioTTM21.501.0007.930[1 - 100]
returnOnEquityTTM1.0332.503.3410.00[0.1 - 1.5]
freeCashFlowPerShareTTM13.762.005.416.24[0 - 30]
dividendYielPercentageTTM3.201.50010.000[0 - 0.4]
operatingCashFlowPerShareTTM15.832.004.729.44[0 - 30]
payoutRatioTTM0.6781.5003.22-3.22[0 - 1]
pegRatioTTM0.6221.5009.190[0.5 - 2]
operatingCashFlowSalesRatioTTM0.3001.0004.990[0.1 - 0.5]
Total Score6.55

Amgen Inc

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.

О Торговые сигналы

Данные торговые сигналы, представленные на этой странице, помогают определить, когда следует ПОКУПАТЬ или ПРОДАВАТЬ NA. Сигналы имеют задержку более 1 минуты. Пожалуйста, примите во внимание, что существует вероятность ошибки или неточностей в силу различных микро и макро факторов влияющих на фондовые рынки.

Данные тор“о”ые сигна“ы не являются определен“ыми, и getagraph.com не несет ответственности за какие-либо действия, предпринятые в от“ошении этих сигналов, как описано в Terms of Use. Сигналы основаны на широком спектре индикаторов технического анализа